Who are Neridronate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Boniva, Zometa, Fosamax, Aredia, Bisphonal, Risedronate/Cholecalciferol combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/neridronate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Neridronate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neridronate (Neridronate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Bone.

phase 3 Farnesyl pyrophosphate synthase Bone Small molecule Live · refreshed every 30 min

Target snapshot

Neridronate (Neridronate) — Ente Ospedaliero Ospedali Galliera.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Neridronate TARGET	Neridronate	Ente Ospedaliero Ospedali Galliera	phase 3		Farnesyl pyrophosphate synthase
Boniva	IBANDRONIC ACID	Hoffmann La Roche	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	2003-01-01
Zometa	ZOLEDRONIC ACID	Novartis	marketed	zoledronic acid	Farnesyl pyrophosphate synthase	2001-01-01
Fosamax	ALENDRONIC ACID	Merck And Co Inc	marketed	Vitamin D [EPC]	Farnesyl pyrophosphate synthase	1995-01-01
Aredia	PAMIDRONIC ACID		marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	1991-01-01
Bisphonal	INCADRONIC ACID	Astellas Pharma	marketed	incadronic acid	Farnesyl pyrophosphate synthase
Risedronate/Cholecalciferol combination	Risedronate/Cholecalciferol combination	Hanlim Pharm. Co., Ltd.	marketed	Bisphosphonate + vitamin D3 combination	Osteoclast farnesyl pyrophosphate synthase (risedronate); vitamin D receptor (cholecalciferol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-12-05 — Fosamax · 9592195 · US

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Neridronate — Competitive Intelligence Brief. https://druglandscape.com/ci/neridronate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing